Predominant expression of CCL2 at the tumor site of prostate cancer patients directs a selective loss of immunological tolerance to CCL2 that could be amplified in a beneficial manner
The Journal of Immunology (2010) - Comments
pubmed: 19995900  doi: 10.4049/jimmunol.0902725  issn: 1550-6606  issn: 0022-1767 

Liat Izhak, Gizi Wildbaum, Uri Weinberg, Weinberg Uri, Yuval Shaked, Jennifer Alami, Daniel Dumont, Boris Friedman, Avi Stein, Nathan Karin